CS224891A3 - System for transferring medicament causing interaction between a protein or a polypeptide and a hydrophobic biologically degradable polymer - Google Patents

System for transferring medicament causing interaction between a protein or a polypeptide and a hydrophobic biologically degradable polymer Download PDF

Info

Publication number: CS224891A3
Authority: CS; Czechoslovakia
Prior art keywords: polypeptide; protein; polymer; hormone; calcitonin
Prior art date: 1990-07-19

Application number

CS912248A

Other languages

Czech (cs)

English (en)

Inventor

Patrick P Deluca

Original Assignee

Univ Kentucky Res Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-07-19

Filing date

1991-07-19

Publication date

1992-03-18

1991-07-19 Application filed by Univ Kentucky Res Found filed Critical Univ Kentucky Res Found

1992-03-18 Publication of CS224891A3 publication Critical patent/CS224891A3/cs

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 93
102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 85
229920001184 polypeptide Polymers 0.000 title claims abstract description 82
108090000623 proteins and genes Proteins 0.000 title claims abstract description 79
102000004169 proteins and genes Human genes 0.000 title claims abstract description 78
230000002209 hydrophobic effect Effects 0.000 title claims abstract description 20
230000003993 interaction Effects 0.000 title claims description 12
239000003814 drug Substances 0.000 title description 49
229920006237 degradable polymer Polymers 0.000 title 1
229920000642 polymer Polymers 0.000 claims abstract description 95
238000000034 method Methods 0.000 claims abstract description 52
239000004005 microsphere Substances 0.000 claims abstract description 30
238000012377 drug delivery Methods 0.000 claims abstract description 28
238000013270 controlled release Methods 0.000 claims abstract description 16
229920002988 biodegradable polymer Polymers 0.000 claims abstract description 14
239000004621 biodegradable polymer Substances 0.000 claims abstract description 14
230000010399 physical interaction Effects 0.000 claims abstract description 11
238000001727 in vivo Methods 0.000 claims abstract description 8
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 48
239000002904 solvent Substances 0.000 claims description 43
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 27
229920000954 Polyglycolide Polymers 0.000 claims description 27
108060001064 Calcitonin Proteins 0.000 claims description 26
102000055006 Calcitonin Human genes 0.000 claims description 25
239000004633 polyglycolic acid Substances 0.000 claims description 25
229960004015 calcitonin Drugs 0.000 claims description 23
239000000203 mixture Substances 0.000 claims description 23
229920001577 copolymer Polymers 0.000 claims description 21
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
239000002244 precipitate Substances 0.000 claims description 15
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 12
229920000747 poly(lactic acid) Polymers 0.000 claims description 12
229920000728 polyester Polymers 0.000 claims description 12
230000008569 process Effects 0.000 claims description 12
239000004626 polylactic acid Substances 0.000 claims description 11
229940088597 hormone Drugs 0.000 claims description 10
239000005556 hormone Substances 0.000 claims description 10
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
-1 soy-tostatin Chemical compound 0.000 claims description 8
239000002253 acid Substances 0.000 claims description 7
JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 claims description 6
108090001061 Insulin Proteins 0.000 claims description 6
102000004877 Insulin Human genes 0.000 claims description 6
108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 6
108090000445 Parathyroid hormone Proteins 0.000 claims description 6
102000003982 Parathyroid hormone Human genes 0.000 claims description 6
229920001710 Polyorthoester Polymers 0.000 claims description 6
102000013275 Somatomedins Human genes 0.000 claims description 6
229940125396 insulin Drugs 0.000 claims description 6
229960001319 parathyroid hormone Drugs 0.000 claims description 6
239000000199 parathyroid hormone Substances 0.000 claims description 6
BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 claims description 5
108010064733 Angiotensins Proteins 0.000 claims description 5
102000015427 Angiotensins Human genes 0.000 claims description 5
108010051479 Bombesin Proteins 0.000 claims description 5
102000013585 Bombesin Human genes 0.000 claims description 5
108010092674 Enkephalins Proteins 0.000 claims description 5
102400000921 Gastrin Human genes 0.000 claims description 5
108010052343 Gastrins Proteins 0.000 claims description 5
108060003199 Glucagon Proteins 0.000 claims description 5
URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 claims description 5
101800001814 Neurotensin Proteins 0.000 claims description 5
102400001103 Neurotensin Human genes 0.000 claims description 5
101800000989 Oxytocin Proteins 0.000 claims description 5
102400000050 Oxytocin Human genes 0.000 claims description 5
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 claims description 5
229920002732 Polyanhydride Polymers 0.000 claims description 5
108010087230 Sincalide Proteins 0.000 claims description 5
108010056088 Somatostatin Proteins 0.000 claims description 5
102000005157 Somatostatin Human genes 0.000 claims description 5
108010003205 Vasoactive Intestinal Peptide Proteins 0.000 claims description 5
230000001746 atrial effect Effects 0.000 claims description 5
DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 claims description 5
238000010609 cell counting kit-8 assay Methods 0.000 claims description 5
AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 claims description 5
229960000258 corticotropin Drugs 0.000 claims description 5
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims description 5
239000002934 diuretic Substances 0.000 claims description 5
229960004666 glucagon Drugs 0.000 claims description 5
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 5
VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 claims description 5
230000001452 natriuretic effect Effects 0.000 claims description 5
PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 claims description 5
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 claims description 5
229960001723 oxytocin Drugs 0.000 claims description 5
IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 claims description 5
229960000553 somatostatin Drugs 0.000 claims description 5
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 5
239000000725 suspension Substances 0.000 claims description 5
RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims description 4
108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 claims description 4
102400000748 Beta-endorphin Human genes 0.000 claims description 4
101800005049 Beta-endorphin Proteins 0.000 claims description 4
102100024881 C3 and PZP-like alpha-2-macroglobulin domain-containing protein 8 Human genes 0.000 claims description 4
101800000414 Corticotropin Proteins 0.000 claims description 4
108010000437 Deamino Arginine Vasopressin Proteins 0.000 claims description 4
108050009340 Endothelin Proteins 0.000 claims description 4
102000002045 Endothelin Human genes 0.000 claims description 4
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 claims description 4
108010004977 Vasopressins Proteins 0.000 claims description 4
102000002852 Vasopressins Human genes 0.000 claims description 4
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims description 4
WOPZMFQRCBYPJU-NTXHZHDSSA-N beta-endorphin Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 WOPZMFQRCBYPJU-NTXHZHDSSA-N 0.000 claims description 4
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims description 4
BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 claims description 4
239000002745 poly(ortho ester) Substances 0.000 claims description 4
229960003726 vasopressin Drugs 0.000 claims description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 claims description 3
229960004281 desmopressin Drugs 0.000 claims description 3
NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 claims description 3
238000004108 freeze drying Methods 0.000 claims description 3
VBZWSGALLODQNC-UHFFFAOYSA-N hexafluoroacetone Chemical compound FC(F)(F)C(=O)C(F)(F)F VBZWSGALLODQNC-UHFFFAOYSA-N 0.000 claims description 3
239000003488 releasing hormone Substances 0.000 claims description 3
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 2
239000012062 aqueous buffer Substances 0.000 claims description 2
238000001816 cooling Methods 0.000 claims description 2
230000001105 regulatory effect Effects 0.000 claims description 2
238000000638 solvent extraction Methods 0.000 claims description 2
230000004936 stimulating effect Effects 0.000 claims description 2
102000051325 Glucagon Human genes 0.000 claims 4
102000008072 Lymphokines Human genes 0.000 claims 4
108010074338 Lymphokines Proteins 0.000 claims 4
KKNIUBFRGPFELP-UHFFFAOYSA-N secretolin Chemical compound N=1C=CNC=1CC(N)C(=O)NC(CO)C(=O)NC(CC(O)=O)C(=O)NCC(=O)NC(C(C)O)C(=O)NC(C(=O)NC(C(=O)NC(CO)C(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC(O)=O)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC(C)C)C(=O)NC(CCC(N)=O)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(N)=O)C(=O)NCC(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(O)=O)C(C)O)CC1=CC=CC=C1 KKNIUBFRGPFELP-UHFFFAOYSA-N 0.000 claims 4
239000000275 Adrenocorticotropic Hormone Substances 0.000 claims 3
239000000637 Melanocyte-Stimulating Hormone Substances 0.000 claims 3
108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 claims 3
102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 claims 2
102400000739 Corticotropin Human genes 0.000 claims 2
108700012941 GNRH1 Proteins 0.000 claims 2
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims 2
102000018997 Growth Hormone Human genes 0.000 claims 2
108010051696 Growth Hormone Proteins 0.000 claims 2
239000000122 growth hormone Substances 0.000 claims 2
210000001685 thyroid gland Anatomy 0.000 claims 2
108010016626 Dipeptides Proteins 0.000 claims 1
102000003886 Glycoproteins Human genes 0.000 claims 1
108090000288 Glycoproteins Proteins 0.000 claims 1
102000009151 Luteinizing Hormone Human genes 0.000 claims 1
108010073521 Luteinizing Hormone Proteins 0.000 claims 1
210000003038 endothelium Anatomy 0.000 claims 1
229940040129 luteinizing hormone Drugs 0.000 claims 1
210000002752 melanocyte Anatomy 0.000 claims 1
229940126701 oral medication Drugs 0.000 claims 1
229920000151 polyglycol Polymers 0.000 claims 1
239000010695 polyglycol Substances 0.000 claims 1
230000006916 protein interaction Effects 0.000 claims 1
238000000710 polymer precipitation Methods 0.000 abstract description 4
229940079593 drug Drugs 0.000 description 42
239000012071 phase Substances 0.000 description 29
229960003773 calcitonin (salmon synthetic) Drugs 0.000 description 25
108010068072 salmon calcitonin Proteins 0.000 description 25
239000000243 solution Substances 0.000 description 22
239000006185 dispersion Substances 0.000 description 17
239000003795 chemical substances by application Substances 0.000 description 13
239000011324 bead Substances 0.000 description 10
241000972773 Aulopiformes Species 0.000 description 9
239000012528 membrane Substances 0.000 description 9
235000019515 salmon Nutrition 0.000 description 9
239000006228 supernatant Substances 0.000 description 8
239000004094 surface-active agent Substances 0.000 description 8
238000002360 preparation method Methods 0.000 description 7
239000000126 substance Substances 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 6
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
239000000872 buffer Substances 0.000 description 6
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
239000011159 matrix material Substances 0.000 description 6
238000001556 precipitation Methods 0.000 description 6
VAIZVCMDJPBJCM-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-one;trihydrate Chemical compound O.O.O.FC(F)(F)C(=O)C(F)(F)F.FC(F)(F)C(=O)C(F)(F)F VAIZVCMDJPBJCM-UHFFFAOYSA-N 0.000 description 5
239000003085 diluting agent Substances 0.000 description 5
238000009826 distribution Methods 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
238000000605 extraction Methods 0.000 description 5
238000010348 incorporation Methods 0.000 description 5
229960000448 lactic acid Drugs 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
230000004001 molecular interaction Effects 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
239000008363 phosphate buffer Substances 0.000 description 5
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
239000011575 calcium Substances 0.000 description 4
229910052791 calcium Inorganic materials 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
238000007918 intramuscular administration Methods 0.000 description 4
239000004310 lactic acid Substances 0.000 description 4
238000011068 loading method Methods 0.000 description 4
239000002245 particle Substances 0.000 description 4
239000000047 product Substances 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
239000008103 glucose Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
239000003094 microcapsule Substances 0.000 description 3
239000000178 monomer Substances 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
239000011148 porous material Substances 0.000 description 3
239000007787 solid Substances 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
230000002459 sustained effect Effects 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
230000035899 viability Effects 0.000 description 3
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
240000007124 Brassica oleracea Species 0.000 description 2
235000003899 Brassica oleracea var acephala Nutrition 0.000 description 2
235000012905 Brassica oleracea var viridis Nutrition 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 2
CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
229920002683 Glycosaminoglycan Polymers 0.000 description 2
238000004566 IR spectroscopy Methods 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 2
102100027467 Pro-opiomelanocortin Human genes 0.000 description 2
241000277331 Salmonidae Species 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000013543 active substance Substances 0.000 description 2
229940024606 amino acid Drugs 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
239000003430 antimalarial agent Substances 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
235000006708 antioxidants Nutrition 0.000 description 2
229960001230 asparagine Drugs 0.000 description 2
229960005261 aspartic acid Drugs 0.000 description 2
230000000975 bioactive effect Effects 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
230000002254 contraceptive effect Effects 0.000 description 2
JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
238000000113 differential scanning calorimetry Methods 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000006911 enzymatic reaction Methods 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
238000007710 freezing Methods 0.000 description 2
230000008014 freezing Effects 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
229920001519 homopolymer Polymers 0.000 description 2
230000001184 hypocalcaemic effect Effects 0.000 description 2
238000002955 isolation Methods 0.000 description 2
239000007951 isotonicity adjuster Substances 0.000 description 2
235000014655 lactic acid Nutrition 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000003589 local anesthetic agent Substances 0.000 description 2
229960005015 local anesthetics Drugs 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
239000011859 microparticle Substances 0.000 description 2
239000003887 narcotic antagonist Substances 0.000 description 2
210000004789 organ system Anatomy 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
230000008884 pinocytosis Effects 0.000 description 2
238000012667 polymer degradation Methods 0.000 description 2
XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 2
BBBFJLBPOGFECG-UHFFFAOYSA-N salmon calcitonin Chemical compound C=1N=CNC=1CC(C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(N)=O)C(=O)NC(C(C)O)C(=O)NC(CC=1C=CC(O)=CC=1)C(=O)N1C(CCC1)C(=O)NC(CCCNC(N)=N)C(=O)NC(C(C)O)C(=O)NC(CC(N)=O)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CO)C(=O)NCC(=O)NC(C(C)O)C(=O)N1C(CCC1)C(N)=O)NC(=O)C(CC(C)C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(N)=O)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CC(C)C)NC(=O)C(C(C)C)NC(=O)C1CSSCC(N)C(=O)NC(CO)C(=O)NC(CC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)N1 BBBFJLBPOGFECG-UHFFFAOYSA-N 0.000 description 2
230000007017 scission Effects 0.000 description 2
229920002379 silicone rubber Polymers 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000007921 spray Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
229920001059 synthetic polymer Polymers 0.000 description 2
230000008685 targeting Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
HEBNOKIGWWEWCN-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-one;hydrate Chemical group O.FC(F)(F)C(=O)C(F)(F)F HEBNOKIGWWEWCN-UHFFFAOYSA-N 0.000 description 1
HLLSOEKIMZEGFV-UHFFFAOYSA-N 4-(dibutylsulfamoyl)benzoic acid Chemical compound CCCCN(CCCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 HLLSOEKIMZEGFV-UHFFFAOYSA-N 0.000 description 1
SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
208000004998 Abdominal Pain Diseases 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
239000001904 Arabinogalactan Substances 0.000 description 1
229920000189 Arabinogalactan Polymers 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
GPKMZACUUQFPGH-UHFFFAOYSA-N C=NS(=O)=O Chemical group C=NS(=O)=O GPKMZACUUQFPGH-UHFFFAOYSA-N 0.000 description 1
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
102100038518 Calcitonin Human genes 0.000 description 1
102000017631 Calcitonin-like Human genes 0.000 description 1
108050005865 Calcitonin-like Proteins 0.000 description 1
241000282461 Canis lupus Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
208000002881 Colic Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
229920001651 Cyanoacrylate Polymers 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
101000741447 Gallus gallus Calcitonin Proteins 0.000 description 1
102400000321 Glucagon Human genes 0.000 description 1
101000741445 Homo sapiens Calcitonin Proteins 0.000 description 1
WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
JVTAAEKCZFNVCJ-REOHCLBHSA-N L-Lactic acid Natural products C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
235000019454 L-leucine Nutrition 0.000 description 1
239000004395 L-leucine Substances 0.000 description 1
241001082241 Lythrum hyssopifolia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
208000010191 Osteitis Deformans Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
208000027868 Paget disease Diseases 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920001244 Poly(D,L-lactide) Polymers 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
239000004365 Protease Substances 0.000 description 1
238000001069 Raman spectroscopy Methods 0.000 description 1
241000700159 Rattus Species 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
108010086019 Secretin Proteins 0.000 description 1
102100037505 Secretin Human genes 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000000078 anti-malarial effect Effects 0.000 description 1
239000002518 antifoaming agent Substances 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
235000019312 arabinogalactan Nutrition 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011648 beta-carotene Substances 0.000 description 1
235000013734 beta-carotene Nutrition 0.000 description 1
TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
229960002747 betacarotene Drugs 0.000 description 1
229920000229 biodegradable polyester Polymers 0.000 description 1
239000004622 biodegradable polyester Substances 0.000 description 1
229920013641 bioerodible polymer Polymers 0.000 description 1
230000009141 biological interaction Effects 0.000 description 1
230000008512 biological response Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
244000309464 bull Species 0.000 description 1
230000000125 calcaemic effect Effects 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
OEERIBPGRSLGEK-UHFFFAOYSA-N carbon dioxide;methanol Chemical compound OC.O=C=O OEERIBPGRSLGEK-UHFFFAOYSA-N 0.000 description 1
125000005518 carboxamido group Chemical group 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
238000013267 controlled drug release Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000002826 coolant Substances 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000000151 deposition Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000004996 female reproductive system Anatomy 0.000 description 1
230000035558 fertility Effects 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 1
XXMIOPMDWAUFGU-UHFFFAOYSA-N hexane-1,6-diol Chemical compound OCCCCCCO XXMIOPMDWAUFGU-UHFFFAOYSA-N 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
229940045644 human calcitonin Drugs 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
229910001867 inorganic solvent Inorganic materials 0.000 description 1
239000003049 inorganic solvent Substances 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
229960003136 leucine Drugs 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
208000027202 mammary Paget disease Diseases 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000008018 melting Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
239000011785 micronutrient Substances 0.000 description 1
235000013369 micronutrients Nutrition 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
229920005615 natural polymer Polymers 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
230000006911 nucleation Effects 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000002357 osmotic agent Substances 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
229960005190 phenylalanine Drugs 0.000 description 1
UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
239000006069 physical mixture Substances 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
229920001610 polycaprolactone Polymers 0.000 description 1
238000012643 polycondensation polymerization Methods 0.000 description 1
238000006068 polycondensation reaction Methods 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000015277 pork Nutrition 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
238000010791 quenching Methods 0.000 description 1
230000000171 quenching effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000013341 scale-up Methods 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
229960002101 secretin Drugs 0.000 description 1
OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
238000000935 solvent evaporation Methods 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
238000005507 spraying Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
229960004306 sulfadiazine Drugs 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
229920002994 synthetic fiber Polymers 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
238000004073 vulcanization Methods 0.000 description 1
OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Compositions Of Macromolecular Compounds (AREA)
Adjustment And Processing Of Grains (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

CS912248A 1990-07-19 1991-07-19 System for transferring medicament causing interaction between a protein or a polypeptide and a hydrophobic biologically degradable polymer CS224891A3 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US55442790A	1990-07-19	1990-07-19

Publications (1)

Publication Number	Publication Date
CS224891A3 true CS224891A3 (en)	1992-03-18

Family

ID=24213291

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CS912248A CS224891A3 (en)	1990-07-19	1991-07-19	System for transferring medicament causing interaction between a protein or a polypeptide and a hydrophobic biologically degradable polymer

Country Status (17)

Country	Link
US (2)	US6306406B1 (fr)
EP (1)	EP0467389B1 (fr)
JP (1)	JPH05103838A (fr)
AT (1)	ATE185269T1 (fr)
AU (1)	AU656897B2 (fr)
CA (1)	CA2046830C (fr)
CS (1)	CS224891A3 (fr)
DE (1)	DE69131677T2 (fr)
DK (1)	DK0467389T3 (fr)
ES (1)	ES2138584T3 (fr)
FI (1)	FI104954B (fr)
GR (1)	GR3032056T3 (fr)
MX (1)	MX9100249A (fr)
NO (1)	NO304411B1 (fr)
NZ (1)	NZ238951A (fr)
PT (1)	PT98397B (fr)
ZA (1)	ZA915584B (fr)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5443841A (en)	1992-06-15	1995-08-22	Emisphere Technologies, Inc.	Proteinoid microspheres and methods for preparation and use thereof
US5714167A (en)	1992-06-15	1998-02-03	Emisphere Technologies, Inc.	Active agent transport systems
US5447728A (en) *	1992-06-15	1995-09-05	Emisphere Technologies, Inc.	Desferrioxamine oral delivery system
US5578323A (en) *	1992-06-15	1996-11-26	Emisphere Technologies, Inc.	Proteinoid carriers and methods for preparation and use thereof
US5693338A (en)	1994-09-29	1997-12-02	Emisphere Technologies, Inc.	Diketopiperazine-based delivery systems
US5629020A (en)	1994-04-22	1997-05-13	Emisphere Technologies, Inc.	Modified amino acids for drug delivery
US5541155A (en)	1994-04-22	1996-07-30	Emisphere Technologies, Inc.	Acids and acid salts and their use in delivery systems
US6221367B1 (en)	1992-06-15	2001-04-24	Emisphere Technologies, Inc.	Active agent transport systems
US6099856A (en)	1992-06-15	2000-08-08	Emisphere Technologies, Inc.	Active agent transport systems
US6331318B1 (en)	1994-09-30	2001-12-18	Emisphere Technologies Inc.	Carbon-substituted diketopiperazine delivery systems
US5451410A (en) *	1993-04-22	1995-09-19	Emisphere Technologies, Inc.	Modified amino acids for encapsulating active agents
JPH05202177A (ja) *	1991-09-06	1993-08-10	Teijin Ltd	生分解性共重合体、及びそれを含有する医薬品組成物
GB9211268D0 (en) *	1992-05-28	1992-07-15	Ici Plc	Salts of basic peptides with carboxyterminated polyesters
US5811127A (en)	1992-06-15	1998-09-22	Emisphere Technologies, Inc.	Desferrioxamine oral delivery system
US5792451A (en)	1994-03-02	1998-08-11	Emisphere Technologies, Inc.	Oral drug delivery compositions and methods
FR2693905B1 (fr) *	1992-07-27	1994-09-02	Rhone Merieux	Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
DE69316101T2 (de) *	1992-08-07	1998-10-22	Takeda Chemical Industries Ltd	Herstellung von Mikrokapseln, die wasserlösliche Arzneimittel enthalten
EP0646000A4 (fr) *	1992-11-16	1997-05-02	Univ Mercer	Compositions comprenant des anticorps de neutralisation microencapsules.
UA61046C2 (en)	1992-12-07	2003-11-17	Takeda Chemical Industries Ltd	Sustained-release preparation and method for its manufacture
TW333456B (en)	1992-12-07	1998-06-11	Takeda Pharm Ind Co Ltd	A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5401516A (en)	1992-12-21	1995-03-28	Emisphere Technologies, Inc.	Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof
US5672659A (en) *	1993-01-06	1997-09-30	Kinerton Limited	Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US6221958B1 (en)	1993-01-06	2001-04-24	Societe De Conseils De Recherches Et D'applications Scientifiques, Sas	Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5863985A (en) *	1995-06-29	1999-01-26	Kinerton Limited	Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
JPH08505395A (ja) *	1993-01-06	1996-06-11	キナートンリミティド	生物分解性ポリエステルと生物活性ポリペプチドのイオン分子結合体
US5709861A (en)	1993-04-22	1998-01-20	Emisphere Technologies, Inc.	Compositions for the delivery of antigens
US5958457A (en)	1993-04-22	1999-09-28	Emisphere Technologies, Inc.	Compositions for the delivery of antigens
ES2244367T3 (es)	1993-04-22	2005-12-16	Emisphere Technologies, Inc.	Composiciones para la administracion por via oral.
US5643957A (en)	1993-04-22	1997-07-01	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US6087324A (en) *	1993-06-24	2000-07-11	Takeda Chemical Industries, Ltd.	Sustained-release preparation
KR100369764B1 (ko) *	1994-07-20	2003-05-22	키너톤 리미티드	생분해성폴리에스테르및생활성폴리펩티드의이온성분자결합체
US6001347A (en)	1995-03-31	1999-12-14	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5965121A (en)	1995-03-31	1999-10-12	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US6090958A (en)	1995-03-31	2000-07-18	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5866536A (en)	1995-03-31	1999-02-02	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5650386A (en)	1995-03-31	1997-07-22	Emisphere Technologies, Inc.	Compositions for oral delivery of active agents
BR9604880A (pt)	1995-03-31	1998-05-19	Emisphere Tech Inc	Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
US5989539A (en)	1995-03-31	1999-11-23	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5820881A (en)	1995-04-28	1998-10-13	Emisphere Technologies, Inc.	Microspheres of diamide-dicarboxylic acids
US5824345A (en)	1995-06-07	1998-10-20	Emisphere Technologies, Inc.	Fragrances and flavorants
US5667806A (en)	1995-06-07	1997-09-16	Emisphere Technologies, Inc.	Spray drying method and apparatus
US5750147A (en)	1995-06-07	1998-05-12	Emisphere Technologies, Inc.	Method of solubilizing and encapsulating itraconazole
US6051258A (en)	1995-06-07	2000-04-18	Emisphere Technologies, Inc.	Proteinoid emulsions and methods for preparation and use thereof
WO1997001331A2 (fr)	1995-06-27	1997-01-16	Takeda Chemical Industries, Ltd.	Production de preparations a liberation prolongee
WO1997010197A1 (fr)	1995-09-11	1997-03-20	Emisphere Technologies, Inc.	PROCEDE POUR PREPARER DES DERIVES D'ACIDES φ-AMINOALCANOIQUES A PARTIR DE CYCLOALCANONES
US6270795B1 (en)	1995-11-09	2001-08-07	Microbiological Research Authority	Method of making microencapsulated DNA for vaccination and gene therapy
WO1997017063A1 (fr)	1995-11-09	1997-05-15	Microbiological Research Authority	Adn microencapsule s'appliquant dans des procedes de vaccination et de therapie genique
AU2595697A (en)	1996-03-29	1997-10-22	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
AU3828597A (en)	1996-06-14	1998-01-07	Emisphere Technologies, Inc.	Microencapsulated fragrances and method for preparation
AU779930B2 (en) *	1996-12-11	2005-02-17	Praecis Pharmaceuticals Incorporated	Pharmaceutical formulations for sustained drug delivery
US5968895A (en) *	1996-12-11	1999-10-19	Praecis Pharmaceuticals, Inc.	Pharmaceutical formulations for sustained drug delivery
US5783567A (en) *	1997-01-22	1998-07-21	Pangaea Pharmaceuticals, Inc.	Microparticles for delivery of nucleic acid
US5939381A (en)	1997-02-07	1999-08-17	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US6313088B1 (en)	1997-02-07	2001-11-06	Emisphere Technologies, Inc.	8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
US5990166A (en)	1997-02-07	1999-11-23	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US6060513A (en)	1997-02-07	2000-05-09	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5879681A (en)	1997-02-07	1999-03-09	Emisphere Technolgies Inc.	Compounds and compositions for delivering active agents
US6358504B1 (en)	1997-02-07	2002-03-19	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5876710A (en)	1997-02-07	1999-03-02	Emisphere Technologies Inc.	Compounds and compositions for delivering active agents
US5804688A (en)	1997-02-07	1998-09-08	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5863944A (en)	1997-04-30	1999-01-26	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5962710A (en)	1997-05-09	1999-10-05	Emisphere Technologies, Inc.	Method of preparing salicyloylamino acids
US6867181B1 (en)	1997-06-02	2005-03-15	Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S.	Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
DE19723807C2 (de) *	1997-06-06	2003-04-24	Ferring Gmbh	Verfahren zur Herstellung von Copolyestern
CA2297025A1 (fr) *	1997-07-25	1999-02-04	Sdg, Inc.	Compositions pharmaceutiques a base de polymeres destinees a une administration ciblee d'agents biologiquement actifs
IL122933A (en) *	1998-01-14	2005-03-20	Efrat Biopolymers Ltd	Polymeric carrier for delivery of a bioactive molecule
JP2002501907A (ja)	1998-01-29	2002-01-22	キナートン・リミテッド	吸収可能なマイクロ粒子の製造法
GB9810236D0 (en)	1998-05-13	1998-07-08	Microbiological Res Authority	Improvements relating to encapsulation of bioactive agents
US6406719B1 (en)	1998-05-13	2002-06-18	Microbiological Research Authority	Encapsulation of bioactive agents
EP1096957A1 (fr)	1998-06-18	2001-05-09	Johns Hopkins University School of Medicine	Methodes et reactifs d'administration intramusculaire d'acides nucleiques
US6916490B1 (en)	1998-07-23	2005-07-12	UAB Research Center	Controlled release of bioactive substances
US6607784B2 (en)	2000-12-22	2003-08-19	Baxter International Inc.	Microprecipitation method for preparing submicron suspensions
US6884436B2 (en) *	2000-12-22	2005-04-26	Baxter International Inc.	Method for preparing submicron particle suspensions
US6951656B2 (en)	2000-12-22	2005-10-04	Baxter International Inc.	Microprecipitation method for preparing submicron suspensions
US6977085B2 (en)	2000-12-22	2005-12-20	Baxter International Inc.	Method for preparing submicron suspensions with polymorph control
US20050048126A1 (en)	2000-12-22	2005-03-03	Barrett Rabinow	Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US9700866B2 (en)	2000-12-22	2017-07-11	Baxter International Inc.	Surfactant systems for delivery of organic compounds
US8067032B2 (en)	2000-12-22	2011-11-29	Baxter International Inc.	Method for preparing submicron particles of antineoplastic agents
US7193084B2 (en)	2000-12-22	2007-03-20	Baxter International Inc.	Polymorphic form of itraconazole
DE60231862D1 (de)	2001-02-23	2009-05-20	Genentech Inc	Erodierbare polymere zur injektion
AU2002337692B2 (en)	2001-09-26	2007-09-13	Baxter International Inc.	Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US20060003012A9 (en)	2001-09-26	2006-01-05	Sean Brynjelsen	Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en)	2001-10-19	2006-09-26	Baxter International Inc.	Compositions of and method for preparing stable particles in a frozen aqueous matrix
DE10206517A1 (de) *	2002-02-16	2003-09-04	Stoess & Co Gelatine	Depotarzneimittel, Trägermaterialien für Depotarzneimittel und Verfahren zu deren Herstellung
KR100405879B1 (ko) *	2002-09-19	2003-11-14	키너톤 리미티드	생분해성 폴리에스테르 및 생활성 폴리펩티드의 이온성분자 결합체
IL152574A (en) *	2002-10-31	2009-09-22	Transpharma Medical Ltd	A system for passing through the skin of dry items or dried medicines
US8133505B2 (en)	2002-10-31	2012-03-13	Transpharma Medical Ltd.	Transdermal delivery system for dried particulate or lyophilized medications
ATE477268T1 (de)	2003-01-28	2010-08-15	Ironwood Pharmaceuticals Inc	Zusammensetzungen zur behandlung von magen-darm- störungen
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
US7393537B2 (en) *	2003-04-25	2008-07-01	Allergan, Inc.	Botulinum toxin for treatment of obsessive compulsive finger biting disorder
SI1639011T1 (sl)	2003-06-30	2009-04-30	Domantis Ltd	Pegilirana protitelesa z enojno domeno (dAb)
JP5105578B2 (ja)	2003-11-05	2012-12-26	サーコードバイオサイエンスインコーポレイテッド	細胞接着のモジュレーター
CA2552758A1 (fr) *	2004-01-13	2005-08-04	Vasogenix Pharmaceuticals, Inc.	Procedes pour le traitement d'infarctus myocardique aigu par l'administration du peptide associe au gene de la calcitonine et compositions en contenant
EP1703895A2 (fr) *	2004-01-13	2006-09-27	Vasogenix Pharmaceuticals, Inc.	Composition a liberation controlee pour l'administration de cgrp en cas de problemes cardio-vasculaires et renaux
WO2005070444A2 (fr) *	2004-01-13	2005-08-04	Vasogenix Pharmaceuticals, Inc.	Procedes permettant d'utiliser le cgrp dans des indications cardiovasculaires et renales
EP1711163A2 (fr) *	2004-02-05	2006-10-18	Baxter International Inc.	Dispersions preparees avec des agents autostabilisants
US7563443B2 (en)	2004-09-17	2009-07-21	Domantis Limited	Monovalent anti-CD40L antibody polypeptides and compositions thereof
US8168655B2 (en)	2005-05-17	2012-05-01	Sarcode Bioscience Inc.	Compositions and methods for treatment of eye disorders
US20070142287A1 (en) *	2005-12-20	2007-06-21	Biomed Solutions, Llc	Compositions And Methods For Treatment Of Cancer
US20100222875A1 (en) *	2006-08-08	2010-09-02	Abbott Cardiovascular Systems Inc.	Method for forming a porous stent coating
US8426467B2 (en)	2007-05-22	2013-04-23	Baxter International Inc.	Colored esmolol concentrate
US8722736B2 (en)	2007-05-22	2014-05-13	Baxter International Inc.	Multi-dose concentrate esmolol with benzyl alcohol
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2009013293A (es)	2007-06-04	2010-02-15	Synergy Pharmaceuticals Inc	Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
MX2010004281A (es)	2007-10-19	2010-09-10	Sarcode Corp	Composiciones y metodos para el tratamiento de la retinopatia diabetica.
WO2009139817A2 (fr)	2008-04-15	2009-11-19	Sarcode Corporation	Produit pharmaceutique cristallin et ses procédés de préparation et d'utilisation
EP2810951B1 (fr)	2008-06-04	2017-03-15	Synergy Pharmaceuticals Inc.	Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
CA2730603C (fr)	2008-07-16	2019-09-24	Synergy Pharmaceuticals Inc.	Agonistes de la guanylate cyclase utiles dans le traitement des affections gastro-intestinales, de l'inflammation gastro-intestinale, du cancer gastro-intestinal et d'autres affections
EP2700651B1 (fr)	2008-07-18	2019-04-10	Bristol-Myers Squibb Company	Compositions monovalentes pour la liaison au CD28 et procédés d'utilisation
US8378105B2 (en)	2009-10-21	2013-02-19	Sarcode Bioscience Inc.	Crystalline pharmaceutical and methods of preparation and use thereof
CA2797133C (fr) *	2010-04-27	2019-08-06	Zealand Pharma A/S	Conjugues peptidiques d'antagonistes du recepteur de glp-1 et de gastrine, et leur utilisation
GB201009037D0 (en)	2010-05-28	2010-07-14	Univ Surrey	Compositions and methods for treating disorders associated with atherosclerotic plaques
US8865220B2 (en) *	2010-06-14	2014-10-21	Kaohsiung Medical University	Method for controlled release of parathyroid hormone from encapsulated poly(lactic-glycolic)acid microspheres
BRPI1003424A2 (pt) *	2010-09-08	2013-01-08	Univ Rio De Janeiro	sistema polimÉtrico de confinamento de amilina humana e anÁlogos agonistas, processo e uso; processo de avaliaÇço funcional de amilina liberada
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
KR102302069B1 (ko)	2010-11-10	2021-09-14	인리젠	장기 확대를 위한 주사가능 제제
ES2579319T3 (es)	2011-05-04	2016-08-09	Balance Therapeutics, Inc.	Derivados de pentilenotetrazol
SI3715345T1 (sl)	2012-07-25	2024-07-31	Bausch + Lomb Ireland Limited	Priprava zaviralca lfa-1
EP3901251B9 (fr)	2012-10-24	2025-06-18	ProKidney	Populations de cellules rénales et leurs utilisations
WO2014120916A1 (fr)	2013-02-01	2014-08-07	Bristol-Myers Squibb Company	Anticorps à domaines pegylés monovalents pour la liaison à cd28 et leurs méthodes d'utilisation
EP3718557A3 (fr)	2013-02-25	2020-10-21	Bausch Health Ireland Limited	Agoniste du récepteur de la guanylate cyclase sp-333 à utiliser lors du nettoyage du côlon
JP2016514671A (ja)	2013-03-15	2016-05-23	シナジーファーマシューティカルズインコーポレイテッド	グアニル酸シクラーゼのアゴニストおよびその使用
JP2016514670A (ja)	2013-03-15	2016-05-23	シナジーファーマシューティカルズインコーポレイテッド	他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
WO2015054649A2 (fr)	2013-10-10	2015-04-16	Synergy Pharmaceuticals, Inc.	Agonistes de guanylate cyclase utiles pour le traitement de troubles induits par les opioïdes
JP2019506383A (ja)	2016-01-11	2019-03-07	シナジーファーマシューティカルズインコーポレイテッド	潰瘍性大腸炎を治療するための製剤および方法
WO2018237170A1 (fr)	2017-06-21	2018-12-27	Bertram Timothy A	Cellules rénales bioactives à immuno-privilège pour le traitement d'une maladie rénale
US12161749B2 (en) *	2018-08-24	2024-12-10	North Carolina State University	Microneedle-array patches with glucose-responsive matrix for closed-loop insulin delivery
US12447179B2 (en)	2018-08-31	2025-10-21	Prokidney	Compositions comprising cell-delivered vesicles and uses thereof
WO2024080308A1 (fr) *	2022-10-12	2024-04-18	中外製薬株式会社	Composition contenant un peptide, un tensioactif et un polymère
WO2026050206A1 (fr)	2024-08-27	2026-03-05	Ironwood Pharmaceuticals, Inc.	Combinaisons d'agonistes du récepteur de glp-1 et de guanylate cyclase c (gc-c)

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en) *	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US3977941A (en)	1971-04-20	1976-08-31	Research Corporation	Protein-enzyme complex membranes
US3843446A (en)	1971-04-20	1974-10-22	Research Corp	Preparation of enzymatically active membranes
US4601981A (en)	1971-04-20	1986-07-22	Research Corporation	Enzymatically active protein-enzyme complex membranes
US3972776A (en)	1973-02-26	1976-08-03	Research Corporation	Preparation of protein membranes containing microbial cells
US5366734A (en) *	1981-02-16	1994-11-22	Zeneca Limited	Continuous release pharmaceutical compositions
IE52535B1 (en) *	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
DE3107527A1 (de)	1981-02-27	1982-09-16	Klaus Prof. Dr. 8400 Regensburg Heckmann	Hyperfiltrationsmembranen mit trennschichten aus monomolekularen filmen von tensiden
US4585797A (en)	1981-04-13	1986-04-29	Seton Company	Cosmetic and pharmaceutical sheet material containing polypeptides
US4591501A (en)	1981-04-13	1986-05-27	Seton Company	Cosmetic and pharmaceutical sheet material containing polypeptides
DE3374837D1 (en)	1982-02-17	1988-01-21	Ciba Geigy Ag	Lipids in the aqueous phase
US4557855A (en)	1983-03-28	1985-12-10	Seton Company	Surface active agent compositions
US4494994A (en)	1983-03-28	1985-01-22	Seton Company	Surface active agent compositions containing polypeptides and lignin sulfonic acid
US4818542A (en) *	1983-11-14	1989-04-04	The University Of Kentucky Research Foundation	Porous microspheres for drug delivery and methods for making same
DE3413608A1 (de) *	1984-04-11	1985-10-24	Hoechst Ag, 6230 Frankfurt	Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung
DE3428372A1 (de) *	1984-08-01	1986-02-13	Hoechst Ag, 6230 Frankfurt	Mikrokapseln von regulatorischen peptiden mit kontrollierter freisetzung, verfahren zu ihrer herstellung und injektionszubereitungen
GB8500209D0 (en)	1985-01-04	1985-02-13	Ceskoslovenska Akademie Ved	Synthetic polymeric drugs
US4863735A (en) *	1985-02-19	1989-09-05	Massachusetts Institute Of Technology	Biodegradable polymeric drug delivery system with adjuvant activity
US4897444A (en)	1985-05-31	1990-01-30	The Research Foundation Of The State University Of New York	Immobilized fluorogenic substrates for enzymes; and processes for their preparation
US4871716A (en) *	1986-02-04	1989-10-03	University Of Florida	Magnetically responsive, hydrophilic microspheres for incorporation of therapeutic substances and methods of preparation thereof
US4741872A (en) *	1986-05-16	1988-05-03	The University Of Kentucky Research Foundation	Preparation of biodegradable microspheres useful as carriers for macromolecules
US4962091A (en) *	1986-05-23	1990-10-09	Syntex (U.S.A.) Inc.	Controlled release of macromolecular polypeptides
PT85521B (pt)	1986-08-11	1990-06-29	Innovata Biomed Ltd	Processo para a preparacao de composicoes farmaceuticas que consistem em microcapsulas
US4911928A (en)	1987-03-13	1990-03-27	Micro-Pak, Inc.	Paucilamellar lipid vesicles
WO1988009664A1 (fr) *	1987-06-10	1988-12-15	Massachusetts Institute Of Technology	Systemes de liberation par erosion et diffusion utilisant une matrice de polyphosphazene
GB8714378D0 (en)	1987-06-19	1987-07-22	Hunchplan Ltd	Parenteral delivery of drugs
US4857311A (en) *	1987-07-31	1989-08-15	Massachusetts Institute Of Technology	Polyanhydrides with improved hydrolytic degradation properties
PT88490B (pt) *	1987-09-14	1992-11-30	Novo Nordisk As	Processo para a preparacao de composicoes farmaceuticas para libertacao nao-enterica trans-mucosa contendo monossacaridos ou oligossacaridos
GB2209937B (en) *	1987-09-21	1991-07-03	Depiopharm S A	Water insoluble polypeptides
JP2670680B2 (ja) *	1988-02-24	1997-10-29	株式会社ビーエムジー	生理活性物質含有ポリ乳酸系微小球およびその製造法
EP0354714A3 (fr)	1988-08-12	1991-04-10	Hadassah Medical Organization	Compositions pharmaceutiques renfermant des composés polyaromatiques
US5008116A (en) *	1988-11-14	1991-04-16	Frederick Cahn	Immunostimulatory microsphere
US5019400A (en) *	1989-05-01	1991-05-28	Enzytech, Inc.	Very low temperature casting of controlled release microspheres
CA2071840C (fr) *	1989-11-06	1997-02-04	Edith Mathiowitz	Mode de fabrication de microspheres proteiniques

1991
- 1991-07-11 CA CA002046830A patent/CA2046830C/fr not_active Expired - Fee Related
- 1991-07-12 NZ NZ238951A patent/NZ238951A/en not_active IP Right Cessation
- 1991-07-15 NO NO912769A patent/NO304411B1/no unknown
- 1991-07-16 AU AU80466/91A patent/AU656897B2/en not_active Ceased
- 1991-07-17 FI FI913455A patent/FI104954B/fi not_active IP Right Cessation
- 1991-07-17 ZA ZA915584A patent/ZA915584B/xx unknown
- 1991-07-17 MX MX9100249A patent/MX9100249A/es not_active IP Right Cessation
- 1991-07-19 JP JP3179588A patent/JPH05103838A/ja active Pending
- 1991-07-19 DE DE69131677T patent/DE69131677T2/de not_active Expired - Fee Related
- 1991-07-19 DK DK91112118T patent/DK0467389T3/da active
- 1991-07-19 AT AT91112118T patent/ATE185269T1/de not_active IP Right Cessation
- 1991-07-19 PT PT98397A patent/PT98397B/pt active IP Right Revival
- 1991-07-19 EP EP91112118A patent/EP0467389B1/fr not_active Expired - Lifetime
- 1991-07-19 CS CS912248A patent/CS224891A3/cs unknown
- 1991-07-19 ES ES91112118T patent/ES2138584T3/es not_active Expired - Lifetime
1995
- 1995-06-07 US US08/481,155 patent/US6306406B1/en not_active Expired - Fee Related
1999
- 1999-12-07 GR GR990403145T patent/GR3032056T3/el unknown
2001
- 2001-09-04 US US09/944,369 patent/US20020051808A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DE69131677D1 (de)	1999-11-11
ATE185269T1 (de)	1999-10-15
CA2046830A1 (fr)	1992-01-20
NO912769D0 (no)	1991-07-15
FI913455L (fi)	1992-01-20
CA2046830C (fr)	1999-12-14
AU8046691A (en)	1992-01-23
NO304411B1 (no)	1998-12-14
DK0467389T3 (da)	2000-02-28
EP0467389A3 (fr)	1994-02-02
EP0467389A2 (fr)	1992-01-22
MX9100249A (es)	1992-02-28
PT98397B (pt)	1999-01-29
AU656897B2 (en)	1995-02-23
GR3032056T3 (en)	2000-03-31
DE69131677T2 (de)	2000-02-24
NZ238951A (en)	1994-12-22
ES2138584T3 (es)	2000-01-16
JPH05103838A (ja)	1993-04-27
NO912769L (no)	1992-01-20
US6306406B1 (en)	2001-10-23
ZA915584B (en)	1992-04-29
FI104954B (fi)	2000-05-15
FI913455A0 (fi)	1991-07-17
US20020051808A1 (en)	2002-05-02
PT98397A (pt)	1992-05-29
EP0467389B1 (fr)	1999-10-06

Publication	Publication Date	Title
US6306406B1 (en)	2001-10-23	Drug delivery system involving interaction between protein or polypeptide and hydrophobic biodegradable polymer
Kumar Malik et al.	2007	Recent advances in protein and peptide drug delivery systems
Hu et al.	2004	Preparation and characterization of solid lipid nanoparticles containing peptide
Shi et al.	2005	Current advances in sustained-release systems for parenteral drug delivery
Sanchez et al.	1993	Development of biodegradable microspheres and nanospheres for the controlled release of cyclosporin A
EP0531497B1 (fr)	1997-08-13	Systemes de liberation orale de microparticules
AU2004277419B2 (en)	2007-10-11	Nanoparticulate therapeutic biologically active agents
RU2508093C2 (ru)	2014-02-27	Фармацевтическая композиция, содержащая микрочастицы с поверхностным покрытием
KR101331136B1 (ko)	2013-11-26	약물의 초기 과다 방출 제어를 위한 약물전달 제형 및 이의 제조방법
CN105412935B (zh)	2019-02-19	一种基于n-(2-羟丙基)甲基丙烯酰胺聚合物的纳米粒及其制备方法
DK1742616T3 (en)	2015-01-12	The microsphere-discharge-system for the prolonged delivery and methods of making and using the same
US8137697B1 (en)	2012-03-20	Nanoparticles for protein/peptide delivery and delivery means thereof
US20040013728A1 (en)	2004-01-22	Controlled drug delivery system using the conjugation of drug to biodegradable polyester
KR19990071595A (ko)	1999-09-27	형태학적으로 균일한 마이크로 캡슐의 제조 방법 및 이 방법에의해 제조된 마이크로 캡슐
Maysinger et al.	1997	Drug delivery to the nervous system
Ferreiro et al.	2002	Alginate/poly-L-lysine microparticles for the intestinal delivery of antisense oligonucleotides
Jiang et al.	2000	Pulsatile protein release from a laminated device comprising of polyanhydrides and pH-sensitive complexes
US8449915B1 (en)	2013-05-28	Pharmaceutical composition of nanoparticles
Kim et al.	2004	Albumin loaded microsphere of amphiphilic poly (ethylene glycol)/poly (α-ester) multiblock copolymer
Stevanović	2017	Polymeric micro-and nanoparticles for controlled and targeted drug delivery
Thakur et al.	2015	Recent trends in targeted drug delivery
US20100180464A1 (en)	2010-07-22	Cores and microcapsules suitable for parenteral administration as well as process for their manufacture
Singh et al.	2011	Biodegradable polymeric microspheres as drug carriers; A review
Loo et al.	2018	Hollow microparticles as a superior delivery system over solid microparticles for the encapsulation of peptides
De Villiers et al.	2003	Developments in drug delivery technologies: Molecular and crystal design, cellular response and targeted and site-specific delivery